Table 2 IC50 values of 13 targeted agents in 10 bladder cancer cell lines, with their molecular targets indicated
Drug | Target | HT1376 | J82 | RT4 | T24 | UMUC3 | 5637 | SW780 | 253Â J | 253Â JBV | HT1197 |
|---|---|---|---|---|---|---|---|---|---|---|---|
Afatinib | EGFR: HER2 | NA | 3.93 | 3.08 | 4.41 | 4.54 | 0.43 | 3.7 | 1.85 | 1.53 | NA |
Axitinib | PDGFR: KIT: VEGFR | 8.95 | > 10 | 7.34 | 9.25 | 6.44 | 3.15 | 14.5 | NA | > 10 | > 10 |
Caborazantinib | MET: RET: VEGFR2 | 9.55 | > 10 | 2.93 | NA | > 10 | 9.22 | 6.53 | NA | > 10 | > 10 |
Erlotinib | EGFR | 5.62 | NA | 6.9 | 7.99 | > 10 | 3.41 | > 10 | NA | > 10 | > 10 |
Everolimus | mTOR | 3.77 | 2 | > 10 | 0.33 | 0.67 | 2.2 | > 10 | NA | 1.5 | 0.71 |
GDC-0879 | RAF | NA | NA | NA | NA | NA | NA | NA | NA | > 10 | NA |
Lapatinib | EGFR:ERBB2 | 2.73 | 5.12 | 0.57 | 6.82 | 2.49 | 1.66 | 1.45 | NA | 2.35 | 4.7 |
Lonafanib | FNTB | NA | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | > 10 | NA |
Nutlin-3 | p53-MDM2 interaction | NA | NA | NA | NA | NA | NA | > 10 | NA | > 10 | > 10 |
Gefitinib | AKT1:EGFR | NA | > 10 | > 10 | > 10 | > 10 | 1.14 | NA | 3.11 | 3.8 | NA |
Trametinib | MEK | NA | NA | 2.54 | NA | NA | NA | > 10 | > 10 | NA | NA |
Vermurafenib | BRAF | > 10 | > 10 | NA | NA | > 10 | > 10 | > 10 | NA | > 10 | > 10 |
Vorinostat | HDAC inhibitors Class I, IIa, IIb, IV | 2.48 | 2.95 | 1.52 | 0.9 | 2.35 | 1.2 | 1.36 | NA | 1.07 | 3.47 |